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A review of prostate cancer GWAS  
Abstract 
Prostate cancer (PrCa) is the commonest cancer in men in Europe and the USA. The 
genetic heritability of PrCa is contributed to by both rarely occurring genetic variants with 
higher penetrance and moderate to commonly occurring variants conferring lower risks. The 
number of identified variants belonging to the latter category has increased dramatically in 
the last 10 years with the development of the genome wide association study (GWAS) and 
the collaboration of international consortia that have led to the sharing of large-scale 
genotyping data. Over 40 PrCa GWAS have been reported, with approximately 170 common 
variants now identified.  
Clinical utility of these variants could include strategies for population-based risk stratification 
to target PrCa screening to men with an increased genetic risk of disease development, 
while for those who develop PrCa, identifying genetic variants could allow treatment to be 
tailored based on a genetic profile in the early disease setting. Functional studies of 
identified variants are needed to fully understand underlying mechanisms of disease and 
identify novel targets for treatment. This review will outline the GWAS carried out in PrCa 
and the common variants identified so far, and how these may be utilised clinically in the 
screening for and management of PrCa. 
--------------------------------------------------------------------------------------------------------------------- 
Introduction 
Prostate cancer (PrCa) is the second commonest cancer in men worldwide and the 
commonest cancer in men in the USA and in Europe (417,000 cases in Europe in 2012).[1, 
2] The aetiology of PrCa is multi-factorial and although not yet fully understood, geographical 
and ethnic variations suggest genetic factors have a role as well as environmental and 
lifestyle factors. So far, the most well established risk factors are age, family history and 
ethnicity. These risk factors as well as evidence of the heritability of PrCa from 
epidemiological as well as twin studies point towards a significant genetic component 
contributing to PrCa development. The recent Nordic Twin Study of Cancer estimated the 
variation of PrCa risk attributed to genetic factors to be 57% making it one of the most 
heritable cancers.[2] 
As with other complex diseases, the genetic heritability of PrCa is contributed to by both 
rarely occurring but higher penetrant genetic variants and moderate to commonly occurring 
variants conferring lower risks. Current research on PrCa susceptibility variants can explain 
34.4% of the familial relative risk (FRR) of PrCa, with approximately 6% accounted for by 
rarely occurring variants and 28.4% attributed to more commonly occurring (Minor allele 
frequency (MAF) >1%) SNPs as well as some rarer single nucleotide variants. In the largest 
PrCa genome wide association study (GWAS) and meta-analysis[3] reported recently, 63 
novel  PrCa susceptibility loci were identified bringing the total number of known loci to 167 
(Table 1, Figure 1).  
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Evolution of research into prostate cancer heritability 
The initial research into the genetic predisposition to PrCa focussed on linkage studies in 
PrCa families. Genomic regions and candidate genes associated with risk were identified but 
very few were able to be replicated in subsequent studies. The few significant findings from 
such linkage studies was the identification of 8q24 as a significant PrCa risk region [4] and 
the identification of the missense G84E variant in HOXB13.[5] The latter mutation has mainly 
been reported in populations of European descent and carrier frequencies in men with PrCa 
range between 0.79% (Canada) to 2.99% (Northern Europe), conferring an odds ratio (OR) 
of 3.6-8.6. [6] In a large international sample of PrCa families recruited from the ICPCG 
(International Consortium of Prostate Cancer Genetics) consortium, 5% of families carried 
the G84E variant, with the highest rate observed in families from Finland (22%), followed by 
Sweden (8.2%). [7] The lack of definitive findings from family based linkage studies and the 
candidate gene approach reflects the polygenic nature of PrCa susceptibility. Although rare 
and moderate to highly penetrant risk variants other than HOXB13 are known, the majority of 
familial risk remains unexplained. Even within PrCa families known to carry a rare variant 
such as HOXB13 or BRCA2, there will be men who develop disease in the absence of the 
germline variant in that family. These cases may be attributed to more commonly occurring 
genetic variants conferring lower risks of PrCa development.   
The development of gene association studies and subsequent modern GWAS has allowed 
researchers to overcome the limitations of small samples sizes and restricted number of 
variants investigated in previous linkage mapping studies. The first GWAS reported in 2006 
was carried out in PrCa cases and controls and identified SNPs in chromosome 8q24- in 
fact, 3 separate studies reported around the same time identified and replicated previous 
association results in this region. With the collaboration of large international consortia 
recent GWAS have included tens of thousands of cases and controls and greatly increased 
the power to detect cancer risk variants, including some rarer variants.  Since the initial 
GWAS in 2006,[8] 44 PrCa GWAS have been reported (Listed in NHGRI-EBI Catalogue of 
published GWASs: http://www.ebi.ac.uk/gwas). The advances in DNA sequencing 
technology and the ability to genotype large numbers of DNA samples concurrently on 
custom designed micro-arrays has led to several large PrCa GWAS, some of which have 
combined their data in meta-analyses and in turn have identified approximately 170 PrCa 
susceptibility variants.    
Variants identified by GWAS 
One of the earliest GWAS identified SNPs lying on 8q24; subsequent studies have revealed 
further SNPs in this region. The biological mechanism leading to prostate carcinogenesis 
though is unclear as the risk loci lie in non-coding regions of DNA. The nearest gene to this 
region is MYC, a proto-oncogene disrupted in many cancers. Functional studies including 
chromatin conformation assays, such as 3C, have shown long-range chromatin interactions 
of the 8q24 SNPs and these are thought to influence the expression of genes such as MYC.  
Other data from 3C experiments incorporating multi-target sequencing identified both intra- 
and inter-chromosomal interactions of 8q24 loci.[9] An example of an inter-chromosomal 
interacting gene is CD96 on chromosome 3q13 with multiple interacting loci or ‘hot-spots’ in 
both chromosomal regions. In the same study,[9] 8q24 interactions with genes involved in 
the Wnt signalling pathway were also observed, suggesting that some risk SNPs have 
effects on the expression of multiple genes and may influence several cell signalling 
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pathways. Identifying such interactions will allow better understanding of the biological 
mechanisms leading to PrCa.  
 
In the examples mentioned above, CD96 encodes a membrane protein that is thought to 
play a role in the interactions of activated T and NK cells during the late phase of the 
immune response. It may also have a role in antigen presentation.[10] Based on the 
Biograph platform (an automated hypothesis generating platform utilising data integration 
and data mining to explore biomedical information), CD96 could have a role in PrCa 
development through its interactions with pathways linked to known cancer associated mi-
RNAs such as MIR-127 (BIOGRAPH).[11] The Wnt signalling pathway which was also found 
to interact with 8q24 loci is involved in prostate bud growth and luminal epithelial 
differentiation providing a plausible mechanism linked to PrCa development. Other studies 
have also linked the risk allele of an 8q24 SNP (rs6983267) to enhanced Wnt signalling and 
other genomic regions harbouring PrCa risk SNPs show significant enrichment of Wnt 
signalling genes.[9] 
 
As the number of cases and controls included in modern GWAS has increased, so has the 
yield of new ‘hits’ from each study. In a study reported by Eeles et al in 2008, a two stage 
GWAS identified 7 novel PrCa associated variants in addition to confirming previously 
identified loci. This study included nearly 2000 cases and 2000 controls in stage one, 
followed by over 3000 cases and 3000 controls in stage two. Some of the SNPs identified in 
that study were linked to candidate genes that could be involved in PrCa: MSMB, LMTK2 
and KLK3.  
 
A later GWAS included a 5-fold higher number of cases and controls to genotype 211,155 
SNPs on a custom SNP array, the iCOGS chip. Through the collaborations set up within the 
PRACTICAL (Prostate Cancer Association group To Investigate Cancer Associated 
Alterations in the genome) consortium (http://practical.icr.ac.uk; Figure 2), samples from 32 
studies (25,074 PrCa cases and 24,272 controls) were included in this GWAS and identified 
23 new PrCa susceptibility loci. Although this was the first study to identify susceptibility 
variants associated with aggressive disease, the 16 SNPs that fit this category also 
associated with non-aggressive PrCa, and therefore would not be clinically useful in 
identifying significant PrCa cases, for example those requiring  radical treatment rather than 
non-interventional approaches.  
 
Utilising the iCOGS chip, fine mapping of the HOXB region at 17q21 was carried out to 
analyse the association of common variants of the HOXB genes with PrCa, and to 
investigate the relationship of common variants with the rare but highly penetrant G84E 
HOXB13 mutation.[12] By genotyping 700 SNPs in this region, imputing a further 3195 SNPs 
in cases and controls (approximately 20,000 each), and carrying out haplotype analyses, a 
common variant was found to tag and partially correlate with the rare G84E variant. This 
phenomenon of synthetic association may explain some of the missing heritability of PrCa as 
risk estimates attached to common variants may be significantly underestimated in cases 
where a GWAS signal is underpinned by a rare causative variant. The investigation of such 
synthetic associations is becoming more feasible with the increasing access to genomic data 
from different populations. Rare predisposition variants involved in synthetic association are 
likely to be limited to certain ethnicities and therefore the lack of signal in a multi-ethnic study 
4 
 
for a tag SNP could suggest that investigation of that locus by sequencing may reveal a rare 
causal variant.  
GWAS and meta-analyses 
Recent GWAS projects have combined their data in meta-analyses with other large scale 
genotyping studies to increase study sample and power and in turn increase variant 
identification. One of these recent studies by Al-Olama et al [13] analysed more than 10 
million SNPs from GWASs carried out in populations of different ethnicities (European, 
African, Japanese and Latino populations) and analysed GWAS data for ~43,300 cases and 
~43,700 controls. This led to the identification of 23 new PrCa associated SNPs.[13] This 
approach also allows replication in independent sample sets that overcomes subpopulation 
stratification effects in single population GWASs. Although rs636291 at 1p36 was found to 
be associated with early onset disease in men of European ancestry (OR 1.18, 
P = 2.1 × 10−8), this finding was not replicated in the subsequent OncoArray project 
(discussed below). .  
 
The OncoArray identified prostate cancer risk  
The most recent 63 PrCa risk loci identified were a result of a large GWAS and meta-
analysis[3] carried out by groups in the OncoArray network.[14] The goal of this network is to 
gain new insights into the genetic architecture and mechanisms underlying common cancers 
through the use of a custom designed Illumina array, the OncoArray, to genotype SNPs in 
cases of the most common cancers (breast, ovary, endometrium, lung, colon, prostate) and 
cancer-free controls. Individuals that have a genetic predisposition to cancer such as BRCA1 
and BRCA2 mutation carriers are also included. Each consortium participating in this project 
contributed between 10,000 to 100,000 cases and controls; inclusion of large numbers of 
cases and controls has led to the identification of both common and rare variants associated 
with cancer risk and is likely to identify variants that are shared across cancer types.  
 
The OncoArray project was established, in part, through the efforts of the GAME-ON 
(Genetic Associations & MEchanisms in ONcology) network set up by the NCI (National 
Cancer Institute, USA). GAME-ON brings together international collaborators with the long-
term goal of providing a rigorous knowledge base to enable clinical translation of GWAS 
findings. The importance of post GWAS research has been increasingly recognized as the 
majority of GWAS identified cancer risk SNPs lay in non-coding regions of DNA. Therefore, 
the biological mechanisms underlying PrCa development is not immediately clear.  
Computational methods such as enrichment analysis suggest that a large number of the 
PrCa risk SNPs (as well as other cancer SNPs) are enriched in multiple functional regions 
such as the binding regions of transcription factors or histone modifiers.[15] Experiments are 
required to validate these associations and to further characterise the molecular 
mechanisms underlying variant association with PrCa.  
 
The OncoArray is a high density array comprising nearly 533,000 SNPs (Figure 3), of which 
approximately 70,000 are PrCa associated SNPs derived from a previous multi-ethnic meta-
analysis [13] as well as from fine-mapping of known PrCa loci, and candidate variants. The 
OncoArray was used to genotype 46,939 PrCa cases and 27,910 controls of European 
ancestry.[3]  
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The OncoArray data (46, 939 PrCa cases and 27, 910 controls) were combined with data 
from other large scale genotyping studies including 32, 225 PrCa cases and 33, 202 controls 
(also of European ancestry) to carry out a meta-analysis of more than 140,000 men. This led 
to the identification of 63 novel loci related to PrCa susceptibility. Of these, 52 were identified 
by imputation of the OncoArray genotyping data. Imputation relies on linkage disequilibrium 
(LD) of SNPs which describes the inheritance of specific groups of SNPs that correlate with 
each other due to their relative vicinity in the genome.  This allows a single ‘tag’ SNP to be 
used to infer the genotypes of other SNPs in the same LD block. Incorporation of the large 
GWAS backbone (260,000 SNPs) on the OncoArray allowed investigators to utilise LD to 
increase the power of variant discovery. The large numbers of cases and controls in this 
study also allowed several sub-analyses of clinical and demographic factors such as age at 
disease onset and aggressiveness of PrCa. A novel variant at 6q27 (rs138004030) was 
found to be significantly associated with early onset disease (OR= 1.27; p=2.85x10-8). In an 
analysis of advanced PrCa cases, 4 variants were found to be significantly associated with 
advanced PrCa (P<5x10-8). These were significantly associated with overall PrCa risk but 
when advanced and non-advanced cases were compared, there was only a marginal 
statistically significant difference observed(P<1.0x10-3).[3] 
Several candidate genes were identified among the new 63 PrCa variants; one of these is an 
ATM missense variant rs1800057 (OR=1.16; P=8.15x10-9; G>C [Pro1054Arg]). Although this 
missense mutation has been classified as ‘benign’ in the ClinVar database, ATM has been 
implicated in PrCa development and particularly with aggressive disease. The ATM protein 
is a key checkpoint kinase that acts as a regulator of a wide range of downstream proteins 
including TP53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and 
RAD9, and DNA repair protein NBS1. It is therefore a key player in the DNA damage 
response pathway. Recent studies have investigated the frequency of germline mutations in 
DNA repair genes in PrCa. In familial cases, there was a 7% frequency of mutations 
reported [16]  and in sporadic metastatic castration resistant (mCRPC) cases the frequency 
was even higher at approximately 12%.[17] In both studies, ATM was found to be the 
second most commonly altered gene (after BRCA2) and poorer outcomes were observed in 
mutation carriers. This pattern was confirmed in another recent study, where lethal and 
indolent PrCa cases were retrospectively compared with respect to germline BRCA1, 
BRCA2 and ATM mutations. Those with lethal PrCa had a carrier rate of 6% compared to 
1.44% in those with indolent disease (p=0.0007).[18]  
Another missense variant (rs2066827) was identified in CDKN1B (cyclin dependent kinase 
inhibitor 1B) (OR=1.06; P=2.31x10-9; T>G [Val109Gly]) which belongs to the Cip/Kip family 
of cyclin dependent kinase inhibitors. CDKN1B protein controls cell cycle progression at the 
G1 stage, and in vitro studies have shown levels of CDKN1B to be linked to increased 
tumour size and grade. This particular variant has previously been implicated in familial PrCa 
as well as advanced disease.  
A third candidate gene was identified by a variant in an intron of RASSF3 (rs7968403; 
OR=1.06; P=3.38x10-12). RASSF3 is a GTP-binding plasma membrane protein and is a 
member of the RAS signalling pathway which is aberrant in approximately one third of 
cancers.  
The findings described above are significant as very few risk variants have been found to lie 
within gene sequences. Functional studies of these variants are still required to further 
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delineate aberrant biological pathways but with the development of gene editing techniques 
such as CRISPR, further characterisation of the molecular mechanisms leading a variant to 
cause PrCa development or progression will be possible.  
GWAS in non-European populations 
Most large scale GWAS have been carried out in European populations, but there have 
been studies investigating common risk variants in other ethnic groups and population-
specific differences have been reported. This may partially explain some of the geographical 
differences in PrCa incidence rates. In a study by Marzec et al,[19] 4 SNPs on 8q24 were 
found to contribute to the risk of PrCa development in Chinese men. Although, these 
variants did not reach GWAS significance level, their frequency was considerably higher 
compared with the frequency in European men.[19]  
In a meta-analysis of two GWAS from Japanese (1,583 cases and 3,386 controls) and 
Chinese (1,417 cases and 1,008 controls) populations which included replication in 
independent samples sets (also of Japanese and Chinese men),[20] 2 independent PrCa 
susceptibility loci were reported: rs12791447 at 11p15.4, and rs58262369 at 14q23.2. In 
addition, 33 SNPs of the 100 known (at that time) PrCa SNPs were also found to be 
significant. rs58262369 is located in the 3’-untranslated region (3’-UTR) of ESR2 which 
encodes the oestrogen receptor, ESR2. Animal studies have shown high expression of 
ESR2 in normal prostate epithelial cells and ESR2 knockout mice are found to develop 
prostate hyperplasia.[20] TCGA (The Cancer Genome Atlas) data shows that ESR2 is up-
regulated in prostate tumours compared to normal prostate tissue, however this didn’t 
correlate with increased mRNA expression therefore further study of protein expression in 
tumours is needed. The second significant SNP identified, rs12791447 lies in an intron of 
PPFIBP2 which encodes the PTPRF-interacting protein, binding protein 2 (Liprin Beta 2). 
TCGA data shows that the expression level of this gene is significantly lower in tumours 
compared to normal prostate tissue, and eQTL analysis also linked rs12791447 with 
expression of PPFIBP2. Additionally, this SNP has been shown to map to a strong enhancer 
region and therefore PPFIBP2 has been suggested as the candidate susceptibility gene 
associated with this variant.[20]  
 
Epidemiological data have long shown that the risk of PrCa development as well as the 
mortality rate is increased in men of African descent compared to other ethnicities. 
Explanation of this increased risk is likely to be due to a number of factors including social 
and environmental factors as well as hereditary genetics. Studies of the genetic component 
contributing to the increased risk have identified SNPs in the 8q24 risk region that are 
specific to African men (rs114798100 and rs111906923)[21]. This may be explained by the 
finding that African ancestry is over represented in the 8q24 region. A 2017 GWAS meta-
analysis[22] of African men combined data from 2 PrCa consortia and 2 large PrCa studies 
to compare the genotypes of over 10,000 cases and over 10,000 controls. Two novel signals 
were identified: rs75823044 on 13q34 (OR 1.55, 95% confidence interval (CI) 1.37-1.76), 
and rs78554043 on 22q12.1 (OR 1.62, 95% CI 1.39-1.89). Interestingly, the latter SNP is a 
missense variant in the CHEK2 gene leading to a non-conservative amino acid change 
(Ile448Ser). With the recent data reporting a correlation between mutations (both germline 
and somatic) in DNA repair genes and the development of mCRPC, this may be a significant 
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finding in men of African background who tend to be diagnosed with more aggressive 
disease compared to non-African ancestry men.  
 
As population specific GWAS continue to be carried out and meta-analysed, further ethnic 
and population differences in susceptibility variants are likely to emerge and these may 
partly explain geographical and population differences in PrCa incidence rates as well as 
phenotypic differences observed. These may suggest alternative biological mechanisms 
leading to PrCa in different populations.  
Radiogenomics GWAS 
Definitive treatment of PrCa comprises either radical prostatectomy (RP) or radiotherapy 
(RT) in the form of external beam radiotherapy (EBRT) or brachytherapy. As discussed 
above, a better understanding of germline SNPs may guide the degree of intervention 
offered to a man depending on risk stratification. In those who are in need of definitive 
treatment of localised disease, factors influencing choice of treatment modality include the 
staging of localised tumour, age and comorbidities, as well as a patient’s preferences. In 
those that undergo RP and go on to relapse with localised disease or biochemical 
recurrence only, RT is also often administered as salvage treatment.  
Long-term effects observed after prostate RT include urinary frequency, urgency, erectile 
dysfunction and rectal bleeding. These symptoms are severe in 2-3% of men. [23] Predictive 
markers of both radiation toxicity and radio-resistance could inform decision making at the 
time of planning treatment in an effort to avoid the development of long term side effects and 
optimise outcomes.  The relationship between PrCa risk loci and the development of RT side 
effects has been investigated and there appears to be no increased risk of late radiation 
effects (e.g. urinary frequency and rectal bleeding) in men with a higher risk genetic 
profile.[24]  
The GWAS approach has been utilised to identify common genetic variants that are 
associated with the development of radiation side effects after treatment of PrCa as well as 
other cancer types. These have not been on as large a scale as some of the recent PrCa 
GWAS but have reported several associated SNPs (Table 2).[25-30] The establishment of 
the Radiogenomics Consortium in 2009 has brought together existing collaborative groups to 
allow sharing of expertise, pooling of data, as well as the set-up of replication studies to 
validate results of GWAS involving small sample sizes.[31] As a result, a consortium led 
meta-analysis of 4 radiogenomics GWAS was published in 2016 and identified two further 
SNPs associated with late RT toxicity [25]: rs17599026 on 5q31.2 was associated with 
urinary frequency (OR 3.12, 95% CI 2.08-4.69, P=4.16x10-8) and rs7720298 on 5p15.2 was 
associated with reduced urine stream (OR 2.71, 95% CI 1.90–3.86, P=3.21 × 10−8). 
As with other GWAS identified SNPs, both these variants lie in non-coding regions. 
rs17599026 is located 23bp downstream of exon 20 of the gene KDM3B. This gene encodes 
the protein lysine-specific demethylase 3B and is highly expressed in bladder tissue, 
therefore it could feasibly be disrupted by radiation leading to bladder dysfunction.[25] 
Whether rs17599026 is influencing the expression of KDM3B or is in LD with another locus 
that is influential is yet to be determined as this SNP tags a large LD block containing 
multiple regulatory regions and therefore may also contain the true causal variant. The 
second SNP identified, rs7720298, causes reduced urine stream and lies downstream of 
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exon 30 of DNAH5, which encodes the dynein, axonemal, heavy chain 5 protein that is part 
of a microtubule associated motor protein complex.[25] This complex has an important role 
in the normal function of cilia in the lung and is also expressed in kidney and bladder tissue 
therefore its abnormal expression of this gene may lead to dysfunction in the urinary tract. 
As with rs17599026, this SNP tags an LD block containing transcriptional regulatory regions 
that may in fact contain the causal SNP.  
Utility of GWAS findings 
Prostate cancer susceptibility loci and polygenic risk profiles 
Based on 147 known prostate cancer susceptibility loci (21 SNPs excluded as did not 
replicate in OncoArray GWAS) we can explain approximately 28.4% of FRR. Although the 
OR associated with individual risk variants are low, most range between 1.0-1.6, the PrCa 
risk conferred by risk alleles is cumulative with increasing number of alleles in the germline 
of an individual. With no current population screening programs for PrCa, there may well be 
a unique public health role for using SNP/genetic profiles to stratify men by their risk of PrCa 
and targeting screening to those at increased risk above a certain threshold. Indeed, in the 
latest GWAS and meta-analysis reported by Schumacher et al[32], it was reported that by 
applying the current known PrCa SNPs into a polygenic risk score (PRS), the relative risk 
(RR) of PrCa for men in the top 1% of the risk distribution is 5.71 relative to men in the 25-
75% PRS percentiles (95%CI: 5.04-6.48), and for those in the top 10% the RR is 2.69 
(95%CI: 2.55-2.82). Notably, the PRS effect estimates increased with a positive family 
history or young age of onset (≤55 years). A risk model incorporating a SNP profile along 
with family history information could be used to target screening to those at highest risk. 
Several retrospective studies have analysed the use of risk models incorporating SNP 
profiles as well as other factors such as family history.[33],[34] The Stockholm 3 (STHLM-3) 
study reported in 2015 by Gronberg et al [35] was the first large prospective PrCa screening 
study utilising a screening algorithm which incorporated a genetic profile, in addition to 
plasma biomarkers and a set of clinical variables. This study recruited approximately 48,000 
men aged 50-69 and had a paired design so that each study participant had both a PSA test 
(threshold of ≥3ng/ml) and the STHLM-3 algorithm to assess their PrCa risk. The STHLM-3 
model outperformed PSA screening for the detection of moderate to high risk PrCa (Gleason 
score ≥7) with an AUC for the detection of high risk cancers of 0.76 compared to 0.56 for 
PSA based screening. Use of the study model also reduced the number of overall prostate 
biopsies by one-third, the number of benign biopsies by 44% and the number of low grade 
(Gleason 6) cancers diagnosed by 17%. Interestingly, approximately 20% of Gleason 7 or 
higher cancers detected by the STHLM-3 model had a PSA under 3 and would have been 
missed by PSA based screening. It is difficult to analyse the contribution of the 232 SNP 
profile to the STHLM-3 screening model but all variables in the model contributed to a 
cumulative improvement in the AUC in the multivariate analysis, and were significantly 
associated with high risk PrCa. Further prospective studies are underway to assess the use 
of SNP profiles in the context of population screening. One of these is the BARCODE1 study 
(NCT03158922) in the UK which is currently recruiting to a pilot study with a plan to expand 
the full study to 5000 participants. This study is recruiting men aged 55-69 years from the 
community who will have germline DNA genotyped for the 167 known PrCa risk variants. A 
PRS will be calculated for each participant and men who fall in the top 10% of the risk 
distribution will undergo screening for PrCa by prostate biopsy. The primary endpoint of this 
study will be the association of PRS with prostate biopsy results.  
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PrCa screening currently relies on PSA measurement with or without digital rectal 
examination of the prostate. Large screening studies (PLCO[36] in the USA and ERSPC[37] 
in Europe) have demonstrated the lack of specificity of PSA levels for PrCa detection, with a 
low positive predictive value of approximately 25% which is reflected in the high proportion of 
benign tissue or low grade and clinically insignificant tumours biopsied in these studies. PSA 
levels are known to fluctuate and are influenced by many factors including infections, 
ejaculation and systemic inflammation. The current consensus from regulatory bodies such 
as NICE (National Institute for Clinical Excellence) in the UK and the USPSTF (US 
Preventive Services Task Force) in the USA has been to advise against the use of PSA 
measurement for population screening as the impact of over-diagnosis and overtreatment of 
indolent disease outweighs the benefit of detection of PrCa. Therefore, germline DNA and 
SNP genotypes may be an ideal biomarker to use in a screening program as this is a largely 
constant marker that is easily accessible and requires a single measurement. The data from 
ongoing studies such as BARCODE-1 and STHLM3-MR (incorporating targeted biopsy 
based on MRI of the prostate into the STHLM3 model; NCT02788825) will provide the 
evidence needed to guide new PrCa screening strategies. 
Germline variants influencing somatic alterations 
Studies have been carried out to assess the utility of SNPs as biomarkers for 
clinicopathological features of PrCa. An example of this is a study reported by Luedeke et al 
linking PrCa SNPs to TMPRSS2-ERG fusion status in somatic (tumour) DNA.[38] The 
TMPRSS2-ERG gene fusion occurs in approximately 50% of PrCa cases in European men 
and is an early event in prostate carcinogenesis. It also appears to be associated with early 
onset disease, but isn’t clearly correlated with aggressive disease. In this study, the germline 
DNA of PrCa cases that were gene fusion positive and negative were assessed for 27 
common risk variants; these two subgroups were additionally compared with controls without 
PrCa. Two SNPs were identified to be significantly associated with somatic fusion status: 
rs16901979 (8q24) was enriched in fusion negative cases and rs1859962 (17q24) was 
enriched in fusion positive cases.[38] Interestingly, an additive effect of the genotypes was 
observed, for example homozygous carriers of the 8q24 variant had a frequency of 33% for 
TMPRSS2-ERG fusion compared to the overall frequency of 56%.This study went on to 
functionally assess the interplay between associated germline variants and somatic 
TMPRSS2-ERG using mRNA expression analysis of candidate target genes in fusion- 
positive and negative tumour tissue. Their results suggest that the 17q24 risk allele 
promotes ERG-mediated changes in expression of SOX9 in fusion positive tumours, which is 
not seen in fusion negative tumours. SOX9 is a transcription factor involved in prostate 
epithelial development, consequently, the synergistic effect of germline variant and gene 
fusion could render advantages to precursor cells in tumour formation with up-regulation of 
transcription factors such as SOX9.  
Ascertaining somatic fusion status as well as other molecular markers in subsequent GWAS 
may well identify subtype-specific risk variants in the future. This could lead to their use as 
biomarkers to guide the risk stratification and/ or management of men with PrCa.  
Common variants and precision medicine 
In coming years, it is feasible that we may be able to (quickly and accurately) obtain and 
utilise the germline genetic profile of a man with PrCa at the time of diagnosis to set up a 
personalised treatment pathway according to the risk category indicated by the SNPs in his 
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germline, the presence or absence of risk loci for radiotoxicity, as well as the presence or 
absence of variants (both common and rare) in DNA repair genes and others. Combining 
this information with a somatic genetic profile could lead to a highly personalised treatment 
pathway. 
SNPs as predictors of aggressive prostate cancer 
As well as indicating previously unknown mechanisms of disease, common genetic variants 
may act as predictors of aggressive PrCa in those that are newly diagnosed. This would 
enable more accurate risk stratification and in turn tailored management of an individual’s 
PrCa. Current clinico-pathological biomarkers used to assign risk of disease progression or 
relapse after treatment includes tumour stage, presenting PSA level and Gleason score 
(GS). Studies have assessed the relationship of germline SNPs with treatment outcomes in 
an attempt to define better risk stratification models in this context.  
In a study of men undergoing either surgery or active surveillance for low grade (GS 6) 
PrCa, the genotypes of 23 SNPs were assessed with respect to upgrading of pathological 
grade.[39] In 950 men with a GS 6 PrCa treated with surgery, 3 SNPs were found to be 
significantly associated with upgrade of GS: rs11568818 on chromosome 11, rs2427345 on 
chromosome 20 and rs7141529 on chromosome 14. After correction for multiple testing, 
only the chromosome 11 SNP remained significantly associated with upgrading of GS 
following surgery (OR 1.46, 95% CI: 1.17–1.82 P=0.0009). The 3 SNPs were also assessed 
prospectively in a smaller (n=209) cohort of men with GS 6 cancer managed with active 
surveillance (AS). The hazard ratios analysed for time to upgrade of GS ranged from 3.7 to 
5.3 and were statistically significant for all 3 SNPs.[39]  
 
In another study analysing SNPs prospectively in an AS cohort (n=494 with GS≤7 cancers), 
rs2735839 (KLK3 region on chromosome 19q13) was found to be significantly associated 
with GS reclassification.[40] There was also a suggestive association of another SNP, 
rs752822 (chromosome 5q32). Together, these two risk alleles had an OR of 2.71 (95% CI = 
1.62–4.51, P = 1 × 10−4) in the initial SNP identification phase of the study, and a disease 
reclassification HR of 1.89 (95% CI = 1.13–3.18, P = 0.016) when genotyping 494 men 
managed by AS.  
 
Germline SNPs found to be significantly associated with developing higher grade disease 
which in turn may increase the risk of progression or metastatic disease if not radically 
treated, may well be more accurate biomarkers for risk stratification at diagnosis than those 
currently used. Incorporating a validated genetic profile into the work up of men diagnosed 
with clinically ‘low’ risk PrCa would allow a more informed approach to decision making by 
both patient and clinician. Indeed, if similar germline predictors of outcome are identified for 
men traditionally thought to be at intermediate risk (e.g. GS 7, PSA 10-20) as in the latter 
study discussed, a proportion of men may be safely managed with less interventional 
approaches if they are found to have a low risk genetic profile.  
 
In both the studies discussed above, there are plausible biological mechanisms linking the 
risk variants to PrCa. rs11568818 on chromosome 11 may contribute to PrCa invasiveness 
as it lies in close proximity to the gene, MMP7.[39, 41] This gene encodes matrix 
metalloproteinase 7, and rs11568818 lies 181bp upstream of its transcription start site. The 
base change at this locus is thought to affect the binding of transcription factors which in turn 
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alters MMP7 expression. MMP7 in addition to other matrix metalloproteinases is involved in 
extracellular proteolysis and acts as a modulator of the tumour microenvironment.[42] Up-
regulation of MMPs promotes tumour invasion and metastasis. MMP7 appears to influence a 
number of ligands to achieve this, such as Fas ligand which is a mediator of cell death;[41] 
cleavage of Fas ligand by MMP7 reduces chemotherapeutic induced cellular apoptosis. 
Investigation of MMP7 in PrCa is needed to identify whether similar mechanisms are at play 
when tumours progress and metastasise.  
 
In the second study discussed above,[40] rs2735839 lies within the PSA coding gene KLK3 
and has previously been found to be associated with PrCa risk and aggressive disease in 
several studies.[43] It may be that the association with aggressive PrCa is linked to higher 
PSA levels associated with this SNP and increased diagnoses through PSA screening, 
although the prospective context of the current study suggests an independent association 
with an aggressive phenotype. Further prospective studies are needed to define this 
association further. The 5q32 SNP (rs752822) lies within an intron of CSNK1A1 (Casein 
Kinase 1, Alpha 1) and forms part of the -catenin destruction complex.[40] This complex 
interacts with the Wnt signalling pathway and leads to accumulation of -catenin in the 
nucleus which in turn increases expression of KLK3 and other genes involved in prostate 
carcinogenesis.   
 
Although there are plausible mechanisms linking these SNPs to PrCa development, the 
GWAS utility of ‘tag’ SNPs that lie in LD blocks means that these loci may not be the 
causative variants but instead may be in LD with SNPs in the same region. Fine mapping 
studies post GWAS will be necessary to allow further assessment of other variants in these 
regions.  
 
Decisions related to treatment modality 
As well as markers of radiotoxicity, identification of patients less likely to respond to radiation 
would guide decision making early on in the curative treatment pathway for localised PrCa. 
In a study of common variants of the BRCA1 gene in men who underwent definitive 
treatment for localised PrCa, two BRCA1 SNPs were found to have a significant association 
with lethal PrCa after RT:[44] rs4474733 was associated with a 35% lower risk of lethal PrCa 
and rs8176305 was associated with a two-fold increased risk of lethal PrCa. There was no 
significant association observed in men treated with surgery.[44] 
BRCA1 plays a major role in DNA damage repair and cell cycle control. In PrCa cell lines, 
BRCA1 has been shown to be involved in radiosensitivity, which can be explained by its role 
in repair of double strand DNA breaks induced by radiation. If these results are validated in 
future studies, these SNPs may act as biomarkers of radio-resistance and if utilised 
clinically, may lead to modification of the treatment pathway for men with a specific genetic 
profile. Interestingly, in a retrospective study of outcomes in carriers of rare BRCA mutations 
after radical treatment, men with germline mutations were found to have worse survival rates 
compared to non-carriers when treated with RT but no difference was seen in those treated 
with surgery.[45] This study was not designed to compare outcomes in BRCA mutation 
carriers according to treatment modality, but the observations noted may fit with the patterns 
seen with BRCA1 common variants. A prospective study of outcomes in BRCA mutation 
carriers as well as carriers of common variants is needed to assess this further.   
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As the field of radiogenomics advances both in PrCa as well as other cancer types, genetic 
profiles could be incorporated into already existing normal tissue complication probability 
(NTCP) models to allow personalisation of radiotherapy delivery.[31] Modified pathways may 
include isotoxic dose escalation in those found to be radio-resistant (or radiation tolerant), or 
dose reductions or hyper-fractionation for radiosensitive individuals. In the latter category of 
patients, adding or increasing systemic therapy may also be considered to optimise 
treatment.[31] In a set of simulation experiments by Kerns et al [46] using both a ‘low 
penetrance’ distribution of radiogenomic SNPs as well as a ‘moderate penetrance’ 
distribution, the addition of a set of SNPs to current NTCP models increased the AUC in all 
models and improved discrimination accuracy. For example, in the ‘low penetrance’ 
distribution model, the inclusion of 78 SNPs could increase the AUC to 0.80 compared with 
0.70 using NTCP model alone for the prediction of late effects. In a ‘moderate penetrance’ 
model, the number of SNPs needed is even lower at 47.[46] By utilising more accurate 
models of radiotoxicity that incorporate an individual’s genetic profile, radiotherapy plans can 
be modified to optimise treatment dose while avoiding long term side effects that will impact 
on quality of life.  
Future Directions 
 
The rapid advances and falling costs of DNA sequencing, along with the collaboration 
between international consortia and research groups, have led to an accumulation of data 
that we have yet to fully understand. Although a large number of common variants 
associated with PrCa have been identified through GWAS, the mechanisms explaining 
causality have not been elucidated. Fine mapping studies continue and will help to identify 
causal SNPs that may be in LD with GWAS identified index SNP. Functional studies and 
gene editing techniques will allow characterisation of variant interactions with cell signalling 
and other pathways. This may reveal novel targets for treatment in addition to explaining 
mechanisms of disease.  
The COGS project (Collaborative Oncological Gene-Environment Study) brings together 
international research groups to promote the study of germline variant interactions with 
lifestyle factors and understand the impact of this interaction on PrCa risk (as well as other 
cancers). It is possible that even without fully characterising genetic variants identified thus 
far, that risk alleles may be used as biomarkers of clinico-pathological features or as risk 
stratifiers in the assessment of PrCa cases. Therefore the use of genetic variants in clinical 
practice needs to be established. Indeed, commercial assays incorporating SNPs linked to 
several conditions are already available, many in the form of ‘direct to consumer’ tests which 
utilise DNA extracted from saliva. With the high number of PrCa risk SNPs now known, it is 
likely that commercial assays incorporating these SNPs will become available.  
Approximately 28.4% of the familial relative risk of PrCa can now be explained by 167 known 
common variants. A further ~6% may be explained by rare but higher risk variants such as 
BRCA2 and HOXB13. As we gain a better understanding of the hereditary genetics of PrCa, 
we will be able to utilise this information to generate genetic profiles that can be incorporated 
into screening programs for PrCa. By targeting screening to those most at risk, the current 
drawbacks of PSA based testing including over-biopsy of indolent or benign tissue may be 
avoided. Information from germline genetic profiles related to the risk of aggressive disease 
and radiogenomics among other factors, can be combined with somatic tumour profiles at 
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the time of diagnosis to generate a personalised treatment pathway and work towards 
achieving true precision medicine in the management of PrCa.  
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Table 1: Prostate cancer associated variants discovered through GWAS 
RAF= Risk allele frequency; OR= Odds ratio 
SNP ID Band Alleles^ RAF OR Reference/ PMID 
63 novel SNPs identified on the OncoArray 
rs56391074 1p22.3 A/AT 0.379 1.05 4 
rs34579442 1q21.3 C/CT 0.336 1.07 4 
rs74702681 2p14 T/C 0.022 1.15 4 
rs62106670 2p25.1 T/C 0.379 1.05 4 
rs11691517 2q13 T/G 0.741 1.05 4 
rs34925593 2q31.1 C/T 0.481 1.06 4 
rs59308963 2q33.1 
T/TATTCTG
TC 
0.729 1.05 
4 
rs1283104 3q13.12 G/C 0.379 1.04 4 
rs182314334 3q25.1 T/C 0.895 1.10 4 
rs142436749 3q26.2 G/A 0.012 1.23 4 
rs10793821 5q31.1 T/C 0.573 1.05 4 
rs76551843 5q35.1 A/G 0.991 1.31 4 
rs4976790 5q35.3 T/G 0.113 1.08 4 
rs4711748 6p21.1 T/C 0.225 1.05 4 
rs9469899 6p21.31 A/G 0.357 1.05 4 
rs9296068 6p21.32 T/G 0.651 1.05 4 
rs12665339 6p21.33 G/A 0.167 1.06 4 
rs17621345 7p14.1 A/C 0.741 1.07 4 
rs11452686 7p21.1 T/TA 0.558 1.04 4 
rs527510716 7p22.3 C/G 0.241 1.07 4 
rs10122495 9p13.3 T/A 0.29 1.05 4 
rs1048169 9p22.1 C/T 0.379 1.07 4 
rs1182 9q34.11 A/C 0.220 1.07 4 
rs141536087 10p15.3 GCGCA/G 0.150 1.10 4 
rs1935581 10q23.31 C/T 0.623 1.06 4 
rs7094871 10q25.2 G/C 0.537 1.04 4 
rs547171081 11p11.2 CGG/C 0.470 1.05 4 
rs1881502 11p15.5 T/C 0.190 1.06 4 
rs61890184 11p15.4 A/G 0.124 1.08 4 
rs2277283 11q12.3 C/T 0.313 1.06 4 
rs12785905 11q13.2 C/G 0.048 1.09 4 
rs11290954 11q13.5 AC/A 0.676 1.07 4 
rs1800057 11q22.3 G/C 0.025 1.13 4 
rs138466039 11q24.2 T/C 0.01 1.28 4 
rs878987 11q25 G/A 0.146 1.07 4 
rs2066827 12p13.1 T/G 0.755 1.07 4 
rs10845938 12p13.1 G/A 0.551 1.06 4 
rs7968403 12q14.2 T/C 0.643 1.07 4 
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rs5799921 12q21.33 GA/G 0.699 1.08 4 
rs7295014 12q24.33 G/A 0.34 1.06 4 
rs1004030 14q11.2 T/C 0.59 1.04 4 
rs11629412 14q13.3 C/G 0.578 1.06 4 
rs4924487 15q15.1 C/G 0.84 1.06 4 
rs33984059 15q21.3 A/G 0.978 1.20 4 
rs112293876 15q22.31 C/CA 0.289 1.07 4 
rs11863709 16q21 C/T 0.960 1.17 4 
rs201158093 16q23.3 TAA/TA 0.440 1.05 4 
rs28441558 17p13.1 C/T 0.056 1.14 4 
rs142444269 17q11.2 C/T 0.788 1.08 4 
rs2680708 17q22 G/A 0.605 1.04 4 
rs8093601 18q21.2 C/G 0.44 1.04 4 
rs28607662 18q21.2 C/T 0.096 1.07 4 
rs12956892 18q21.32 T/G 0.30 1.05 4 
rs533722308 18q21.33 CT/C 0.412 1.05 4 
rs10460109 18q22.3 T/C 0.42 1.04 4 
rs11666569 19p13.11 C/T 0.711 1.06 4 
rs118005503 19q12 G/C 0.911 1.11 4 
rs61088131 19q13.2 T/C 0.835 1.05 4 
rs11480453 20q11.21 C/CA 0.602 1.05 4 
rs6091758 20q13.2 G/A 0.464 1.09 4 
rs9625483 22q12.1 A/G 0.027 1.17 4 
rs17321482 23p22.2 C/T 0.866 1.07 4 
rs138004030* 6q27 G/A 0.92 1.28 4 
^Reference allele/ risk allele 
*Associated with early-onset PrCa 
SNPs discovered in European populations 
SNP ID Chromosome Risk alleles RAF OR Reference/ PMID 
rs636291 1 A 0.683 1.04 25217961 
rs17599629 1 G 0.218 1.07 25217961 
rs1218582 1 G 0.4467 1.05 23535732 
rs4245739 1 A 0.738 1.10 20197460, 23535732 
rs11902236 2 T 0.269 1.05 23535732 
rs9287719 2 C 0.467 1.07 25217961 
rs9306895 2 C 0.364 1.08 26025378 
rs1465618 2 T 0.2141 1.09 19767753 
rs721048 2 A 0.1822 1.10 18264098 
rs10187424 2 T 0.5738 1.08 21743467 
rs12621278 2 A 0.9414 1.27 19767753 
rs2292884 2 G 0.2413 1.06 21743057 
rs3771570 2 T 0.1495 1.09 23535732 
rs2660753 3 T 0.1028 1.13 18264097 
rs7611694 3 A 0.579 1.09 23535732 
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rs10934853 3 A 0.277 1.10 19767754 
rs6763931 3 A 0.442 1.04 21743467 
rs10936632 3 A 0.5074 1.10 21743467 
rs10009409 4 T 0.311 1.06 25217961 
rs1894292 4 G 0.515 1.06 23535732 
rs12500426 4 A 0.4632 1.07 19767753 
rs17021918 4 C 0.6507 1.09 19767753 
rs7679673 4 C 0.592 1.13 19767753 
rs2242652 5 G 0.794 1.17 21743467 
rs2121875 5 C 0.33 1.05 21743467 
rs6869841 5 T 0.209 1.04 23535732 
rs4713266 6 C 0.517 1.05 25217961 
rs7767188 6 A 0.210 1.06 25217961 
rs130067 6 G 0.2021 1.05 21743467 
rs3096702 6 A 0.3771 1.06 23535732 
rs3129859 6 G 0.670 1.06 25217961 
rs2273669 6 G 0.1462 1.07 23535732 
rs1933488 6 A 0.5788 1.08 23535732 
rs9364554 6 T 0.2826 1.11 18264097 
rs12155172 7 A 0.220 1.10 23535732 
rs10486567 7 G 0.763 1.14 18264096 
rs56232506 7 A 0.451 1.06 25217961 
rs6465657 7 C 0.4635 1.11 18264097 
rs2928679 8 A 0.437 1.05 19767753 
rs11135910 8 T 0.1529 1.08 23535732 
rs12543663 8 C 0.295 1.12 19767752 
rs10086908 8 T 0.697 1.13 19767752 
rs183373024 8 G 0.007 2.91 23104005 
rs16901979 8 A 0.032 1.56 17401366 
rs620861 8 G 0.631 1.15 19767752 
rs6983267 8 G 0.511 1.22 17401363 
rs1447295 8 A 0.107 1.41 17401363, 17401366 
rs17694493 9 G 0.136 1.08 25217961 
rs1571801 9 T 0.268 1.03 18073375 
rs76934034 10 T 0.917 1.12 25217961 
rs10993994 10 T 0.383 1.23 18264096, 18264097 
rs3850699 10 A 0.700 1.07 23535732 
rs4962416 10 C 0.2668 1.06 18264096 
rs7127900 11 A 0.1985 1.19 19767753 
rs7931342 11 G 0.504 1.17 18264097 
rs11568818 11 T 0.550 1.08 23535732 
rs11214775 11 G 0.709 1.07 25217961 
rs80130819 12 A 0.908 1.10 25217961 
rs10875943 12 C 0.287 1.07 21743467 
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rs902774 12 A 0.1526 1.13 21743057 
rs1270884 12 A 0.482 1.07 23535732 
rs8008270 14 C 0.8139 1.09 23535732 
rs7141529 14 C 0.499 1.05 23535732 
rs8014671 14 G 0.580 1.05 25217961 
rs684232 17 C 0.3534 1.09 23535732 
rs11649743 17 G 0.8055 1.13 18758462 
rs4430796 17 A 0.5253 1.22 17603485 
rs138213197 17 T 0.002 3.85 22236224 
rs11650494 17 A 0.0779 1.10 23535732 
rs1859962 17 G 0.4813 1.17 17603485 
rs7241993 18 C 0.6949 1.08 23535732 
rs8102476 19 C 0.5393 1.09 19767754 
rs11672691 19 G 0.7368 1.10 19318570, 23065704 
rs2735839 19 G 0.8527 1.18 18264097 
rs2427345 20 C 0.621 1.05 23535732 
rs6062509 20 T 0.6983 1.08 23535732 
rs58133635 22 T 0.197 1.07 19117981, 25217961 
rs5759167 22 G 0.502 1.15 19767753 
rs2405942 23 A 0.7833 1.05 23535732 
rs5945619 23 C 0.364 1.11 18264097 
rs2807031 23 C 0.182 1.06 25217961 
rs5919432 23 T 0.8008 1.04 21743467 
rs6625711 23 A 0.1763 1.01 25217961 
rs4844289 23 G 0.384 1.04 25217961 
SNPs discovered in non-European populations 
rs2055109 3 T 0.7643 1.02 22366784 
rs12653946 5 T 0.4246 1.08 20676098 
rs1983891 6 T 0.2773 1.09 20676098 
rs339331 6 T 0.695 1.09 20676098 
rs1512268 8 T 0.4296 1.14 20676098 
rs817826 9 T 0.8552 1.00 23023329 
rs2252004 10 A 0.1017 1.00 22366784 
rs12791447 11 G 0.0747 1.05 26443449 
rs1938781 11 G 0.2297 1.03 22366784 
rs9600079 13 T 0.443 1.01 20676098 
rs58262369 14 C 0.998 1.27 26443449 
rs7210100 17 A 0.0001 1.34 21602798 
rs103294 19 C 0.7812 1.00 23023329 
rs75823044 13 T 0.022 1.55 Reference [22] 
rs78554043 22 C 0.015 1.62 Reference [22] 
SNPs discovered in multi-ancestry populations 
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rs1775148 1 C 0.359 1.04 25217961 
rs9443189 6 A 0.857 1.07 25217961 
rs7153648 14 C 0.082 1.03 25217961 
rs12051443 16 A 0.344 1.03 25217961 
rs12480328 20 T 0.928 1.11 25217961 
rs1041449 21 G 0.433 1.05 25217961 
rs2238776 22 G 0.802 1.05 25217961 
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Table 2: SNPs associated with radiation toxicity 
Locus- 
Nearest 
Gene(s) 
SNP Toxicity 
endpoint 
OR (95% 
confidence 
interval) 
Proposed 
mechanistic 
relationship 
Reference  
5q31.2 – 
KDM3B 
 
rs17599026 Urinary 
frequency (2 
years after 
RT) 
3.12 (2.08–
4.69) 
KDM3B expressed in 
bladder tissue. 
Radiation may lead 
to bladder 
dysfunction due to 
effect on this gene. 
[25] 
5p15.2 – 
DNAH5 
rs7720298 Decreased 
urine stream 
(2 years after 
RT) 
2.71 (1.90–
3.86) 
DNAH5 expressed in 
kidney and bladder 
tissue. Radiation 
may lead to bladder 
dysfunction due to 
effect on this gene. 
 
[24] 
2q24.1 - 
TANC1 
rs264663 Overall 
toxicity, late 
toxicity 
6.6 (2.2-19.6) TANC1 involved in 
repair of muscle 
damage 
[26] 
9p21.2 - 
IFNK and 
MOB3B 
rs17779457 
(one of 8 
SNPs in a 
haplotype 
block) 
Urinary 
symptoms 
e.g. 
incomplete 
emptying, 
intermittency, 
frequency 
No OR 
published. 
Beta 
coefficient 
2.4 
IFNK a member of 
type 1 IFN family 
with a role in 
inflammatory 
response to radiation 
induced tissue 
damage. 
MOB3B essential for 
mitotic checkpoint 
regulation. 
 
 
[27] 
 
11q14.3 - 
SLC36A4 
rs7120482 
rs17630638 
Rectal 
bleeding 
3.1 (1.7-5.6) 
2.9 (1.6-5.2 
SLC36A4 encodes 
amino acid 
transporter needed 
for cellular 
proliferation.  
 
 
[28] 
 
Chr 2 - 
FSHR 
rs2268363 
(GWAS in 
African 
American 
men) 
Erectile 
dysfunction 
OR = 7.03; 
95% CI 3.4–
14.7 
Involved in normal 
testis development. 
Disruption of FSH 
signalling associated 
with abnormal 
spermatogenesis 
and infertility. 
 
[29] 
10q26.3 - 
GLRX3 
19q13.43 - 
rs11017104 
rs7245988 
Erectile 
dysfunction 
1.5 (0.7-3.0) 
2.0 (0.9-4.4) 
12 SNPs identified 
that lie near genes 
involved in biological 
activities of erectile 
 
[30] 
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NLRP11 
 
 
(two of 12 
SNPs 
discovered 
in this 
GWAS) 
function. 
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Figure Legends 
Figure 1. Prostate Cancer Risk Loci 
Figure 1 demonstrates the distribution of loci associated with prostate cancer risk identified 
by GWAS studies (each red arrow represents an individual SNP) 
 
Figure 2. Prostate Cancer Consortia 
Figure 2 shows the consortia and studies investigating the role of genetic variants in prostate 
cancer. Large scale collaborative efforts and data sharing are needed to answer the various 
scientific and clinical questions related to prostate cancer genetics.  Abbreviations and 
acronyms: BARCODE-1: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening 
(IRAS ID147536; Research Ethics Number: 15/LO/1992); BPC3:Breast Prostate Cancer Cohort 
Consortium (http://epi.grants.cancer.gov/BPC3/); CAPS: Cancer in the Prostate in Sweden 
(http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps); CGEMS: The Cancer Marker 
Susceptibility Projects (http://dceg.cancer.gov/research/how-we-study/genomicstudies/cgems-
summary); ELLIPSE: Elucidating Loci Involved in Prostate Cancer 
(http://epi.grants.cancer.gov/gameon/); GENPET: An imaging study of FCH-PET-CT in men with 
prostate cancer and a BRCA gene mutation (IRAS ID 138894) (Research Ethics Number: 
15/20/0242); GENPROS: Analysing outcomes after prostate cancer diagnosis and treatment in 
carriers of rare germline mutation in cancer predisposition genes. (NCT02705846); ICPCG: 
International Consortium of Prostate Cancer Genetics (www.icpcg.org); IMPACT: The Identification of 
Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1/BRCA2 
mutation carriers and controls (www.impact-study.co.uk); MADCaP: Men of African Decent and 
Prostate Cancer (http://epi.grants.cancer.gov/madcap); PRACTICAL: Prostate Cancer Association 
Group to Investigate Cancer Associated Alterations in the Genome 
(http://practical.ccge.medschl.cam.ac.uk); PROFILE: Germline genetic profiling: Correlation with 
targeted prostate cancer screening and treatment (NCT02543905); RGC: Radiogenomics Consortium 
(https://epi.grants.cancer.gov/radiogenomics/). 
 
Figure 3. Composition of the OncoArray BeadChip 
Figure 3 displays the proportion of SNPs assigned to each cancer type. The OncoArray 
genotyping microarray comprises ~533,000 SNPs. SNPs related to genetic modifiers of 
BRCA1/2 were also included as well as common cancer susceptibility loci.  
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